Absci Corporation

NASDAQ:ABSI

Biotechnology

Healthcare
$8.18 +1.04%

+$0.08 today

Market cap
$1.41B
Beta
2.46
P/E (TTM)
-9.4
EPS (TTM)
-$0.77
52W Low $2.24High $8.17

Volume 5.66M

Average 5.10M

Returns on capital

Absci Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-60.8%

avg -36.0%

ROIC

-63.6%

avg -40.7%

ROA

-53.3%

avg -37.0%

Analysis

ROA is currently the strongest return metric at -53.3% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sean McClain

Founder, Chief Executive Officer, President & DirectorUSD 1.08M368.55M5.49%

Zachariah Jonasson

Chief Business Officer & Chief Financial OfficerUSD 816.51K53484.92K0.31%

Christine Lemke

Senior Vice President of Portfolio & Growth Strategy————

Moetaz Albizem

Senior Vice President of Clinical Operations————

Shelby Walker

Chief Legal Officer—51——

Ransi Somaratne FACC

Chief Medical Officer—60——

Alexander Khan

CVP of Finance & Head of Investor Relations————

Todd Bedrick

Senior Vice President & Chief Accounting Officer——199.13K0.13%

Jeanne Schreuder SPHR

Senior Vice President of People & Experience————

Wen Sha

Chief of Staff————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$933,174.38

Sells

2

$132,328.43

Net Transaction Value

+$800,845.95

Net buying

Most Active

Pangalos Menelas N

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 30, 26

Szela Mary T

Direct

Buy$148.9K
May 13, 26

Pangalos Menelas N

Direct

Buy$200.7K
Mar 12, 26

Busch Andreas

Direct

Buy$229K
Feb 27, 26

Pangalos Menelas N

Direct

Buy$205.8K
Feb 2, 26

McClain Sean

Direct

Sell$80K
Feb 2, 26

Jonasson Zachariah

Direct

Sell$52.3K
Dec 5, 25

VAN HOUTEN FRANS

Direct

Buy$148.8K

Summary

Insiders reported 5 buys worth $933,174.38 and 2 sells worth $132,328.43 over the last 12 months. That adds up to net buying of $800,845.95. Pangalos Menelas N was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A-21.3%
+80.6% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at -21.3% over three years. Forward estimates point to Revenue at +80.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Absci Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ABSI's management, answered from reported figures.

Who manages ABSI?

Absci Corporation (ABSI) lists 10 active executives. The top listed executive is Christine Lemke, Senior Vice President of Portfolio & Growth Strategy.

Are ABSI insiders buying or selling?

Recent insider activity shows net buying of $177.95M.